Financial results for Quarter and Financial Year ended on 31 March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd reported its audited standalone financial results for Q4 and FY25. Total revenue for FY25 jumped to ₹84.84 lakhs from ₹16.66 lakhs in FY24, a roughly 5x increase. Profit after tax surged to ₹35.61 lakhs (EPS ₹1.17) versus ₹1.52 lakhs (EPS ₹0.05) last year. However, Q4 FY25 alone posted a loss of ₹8.35 lakhs, reversing the strong full-year gains. The statutory auditor (Andros & Co.) issued an unmodified opinion. The company also appointed a new Independent Director, a new Secretarial Auditor (SBR & Co.), and reconstituted its board committees. The company's business operates in a single segment — Horticulture.
Full-year numbers show a sharp turnaround with strong revenue and profit growth, which is positive for shareholders. However, the Q4 loss and negative operating cash flow of ₹10.19 lakhs signal that the earnings quality and cash generation still need improvement.